Pleural Mesothelioma

Researchers Possibly Found a MicroRNA Biomarker to Diagnose Mesothelioma

Italian researchers have potentially found a new biomarker for mesothelioma. The biomarker is a microRNA signature. This would allow doctors to determine if someone’s cancer is mesothelioma or another type of cancer quickly. Mesothelioma is a notoriously hard to treat cancer and early diagnosis is one of the keys to[…]

Read More »

Report Shows that Asbestos Ban Would Benefit Countries Around the World

Banning asbestos could soon be a reality after a study linked asbestos, a toxic naturally occurring mineral, to mesothelioma, lung cancer, and other cancers. The report linked asbestos with different asbestos related diseases in 70 countries. The report was published in May by Environmental Health Perspectives, which is supported by[…]

Read More »

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Primary Outcome Measures Phase 1 – Establish the recommended Phase 2 dose (RP2D) according to dose-limiting toxicity (DLT) of defined adverse events. [ Time Frame: DLTs within 28 days post-treatment ] Phase 1 -The number and percent of patients in the DLT evaluable set who experienced DLTs from the first administration of study drug[…]

Read More »

An Inhalable Gene Therapy is Being Tested for Mesothelioma

An inhalable gene therapy could potentially be approved for use in mesothelioma patients. Researchers in Japan have created two different tumor suppressing drugs that work by targeting genetic mutations. The drugs were created for non-small cell cancer and pleural mesothelioma. They are both doing well in the laboratory. The drugs[…]

Read More »

SMARTEST Trial Hopes to Improve Survival Times for Mesothelioma

Researchers are performing a clinical trial hoping that they can make pleural mesothelioma a more manageable, and even survivable, disease. The clinical trial is being done at Princess Margaret Cancer Center in Toronto. The trial is known as SMARTEST, which stands for Surgery for Mesothelioma After Radiation Therapy using Exquisite[…]

Read More »

OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

Primary Outcome Measures Determination of ORR for the combination of OT-101 and pembrolizumab in subjects [ Time Frame: approximately 24 months ] modified RECIST (mRECIST; v1.1) Secondary Outcome Measures PFS, DOR and 6-month and 12-month Overall Survival (OS) will be estimated in all subjects in the ITT population. [ Time Frame: approximately 18 months ] Progression-free Survival (PFS),[…]

Read More »

Increasing Levels of Women are Dying from Mesothelioma

Over the past 20 years, the number of women dying from mesothelioma increased by 25 percent. This is happening even with less asbestos being used. Deaths in men have been falling, the reverse of what is happening in women. The information was published in the Morbidity and Mortality Weekly Report[…]

Read More »

Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years (CanBenefitII)

Primary Outcome Measures Recruitment Rate [ Time Frame: 24 weeks ] The Recruitment Rate will be assessed by the number of eligible patients approached vs the number of eligible patients consent for the study, providing a number of non-participations. This will be gathered as an aspect of feasibility. Retention Rate [ Time Frame: 24 weeks ] Retention rate[…]

Read More »

Targeted Therapy is Showing Promising Results for Mesothelioma

Targeted research is advancing the treatment of pleural mesothelioma. Results from a study on a novel protein inhibitor known as tazemetostat (brand name Tazverik) were recently released. It is showing impressive results as a second line treatment for mesothelioma patients with the BAP1 genetic mutation. The control rate for disease[…]

Read More »